Your guide to Proposition 38: Immunology and immunotherapy research funding

See more from the L.A.Times in Google Search.
Set us as preferred Within the first few weeks of the Trump Administration’s return to the White House last year, the president criticized and targeted congressionally approved funding for science, medical and other federal research grants.The president froze or terminated an estimated $3 billion in research grants from agencies that include the National Institutes of Health and National Science Foundation, and at least half remained frozen or canceled at the beginning of this year, according to the Brennan Center for Justice.A more recent study found that of $177 billion in federal grants the president froze across the U.S., at least $126 million was for medical and science research for California, according to a tracking tool created by the States United Democracy Center and Grant Witness organization.To backfill some of the loss in research funding, proponents say Proposition 38 will create a stable source of funding for scientists and medical experts.
If approved by the voters, the measure will provide $8.4 billion in funding for immunology and immunotherapy research that aims to cure and prevent cancer, heart disease and Alzheimer’s disease.California California’s general election takes place on Novemer 3.
Learn about L.A.’s city and county races as well races for state office.Nationwide, medical research and development are funded by both private companies and government agencies such as the National Institutes of Health.In California, voters previously approved additional funding resources, Proposition 71 in 2004 and Proposition 14 in 2020 for stem cell research, according to the Legislative Analyst’s Office.The propositions granted the state authority to issue a combined $8.5 billion in general obligation bonds — a loan that’s repaid with interest over time.Proposition 38 would authorize the state to issue $8.4 billion in bonds to fund immunology and immunotherapy research to uncover tre...